SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
AbCheck s.r.o., a technology company focusing on the discovery and optimization of high-quality human antibodies, announced today the achievement of the first clinical milestone in its antibody discovery collaboration with Eli Lilly and Company of Indianapolis, Indiana, U.S.A. The milestone, the commencement of patient enrollment for a Phase I study of an antibody discovered under the collaboration agreement, triggers an undisclosed milestone payment to AbCheck from Lilly. Further details about the study and antibody were not disclosed.
“This clinical milestone represents an important validation of our unique combination of technology platforms,” commented Dr. Volker Lang, Managing Director of AbCheck. “We are very pleased our technology has enabled the discovery of another antibody that has advanced to the clinic, demonstrating again that our technology is reliably capable of delivering high-quality antibodies suitable for clinical development.”
Under the collaboration agreement, AbCheck has used its antibody discovery libraries to deliver high-affinity, fully human antibodies against an undisclosed number of Lilly targets. The distinct human antibody libraries comprise a total of about 10 billion sequentially and structurally diverse antibodies. Lilly, which has full rights to any antibodies selected, pay AbCheck discovery fees and development milestone payments; other financial and deal terms were not disclosed.
About AbCheck
AbCheck discovers and optimizes human antibodies leveraging several proprietary platforms including in vitro and in vivo technologies. We use phage/yeast display libraries (AbSieve), mass humanization and antibody optimization (AbAccel) to provide high quality leads. Our technology platform can be used in conjunction with all antibody designs and allows selection of optimized leads from a huge number of variants. Flexibly adapting to our partners’ needs, we offer a variety of business models, including deals without royalties. AbCheck has proven its capabilities in multiple partnerships throughout the US and Europe. AbCheck is a wholly owned subsidiary of Affimed GmbH.
For more information: AbCheck s.r.o. Dr. Volker Lang Managing Director +420 378 051500 [email protected]
